Selected Publications from 2024

Publications

Abemaciclib Therapy Using the MonarchE Criteria Results in Large Numbers of Excess Axillary Node Clearances—Time to Pause and Reflect?
Ahari D, Wilkinson M, Ali N, Taxiarchi VP, Dave RV, Gandhi A.
Cancers.   2024  16(17):3072.  https://doi.org/10.3390/cancers16173072
 
Population-based germline testing of BRCA1, BRCA2, and PALB2 in breast cancer patients in the United Kingdom: Evidence to support extended testing, and definition of groups who may not require testing
D. Gareth Evans, Emma R. Woodward, George J. Burghel, Sophie Allen, Beth Torr, Monica Hamill, Grace Kavanaugh, Mike Hubank, Stephen Bremner, Christopher I. Jones, Helene Schlecht, Susan Astley, Sarah Bowers, Sarah Gibbons, Helen Ruane, Caroline Fosbury, Sacha J. Howell, Claire Forde, Fiona Lalloo, William G. Newman, Miriam J. Smith, Anthony Howell, Clare Turnbull, Ashu Gandhi
Genetics in Medicine Open  2024  Volume 2, 100849, ISSN 2949-7744  https://doi.org/10.1016/j.gimo.2023.100849
 
Pathogenic variant detection rate varies considerably in male breast cancer families and sporadic cases: minimal additional contribution beyond BRCA2, BRCA1 and CHEK2
Evans DG, Burghel GJ, Howell SJ, Pugh S, Forde C, Howell A, Lalloo F, Woodward ER
Journal of Medical Genetics   2024  Published Online First: 12 April   doi: 10.1136/jmg-2023-109826
 
Germline testing for breast cancer patients in England: illogical to prioritise grade 1 breast cancer aged 30–39 over grade 3 aged 40–49 years?
Evans DG, Howell SJ, Burghel GJ, Forde C, Lalloo F, Smith MJ, Howell A, Gandhi A, Woodward ER.
J Med Genet 2024;   2024  0:1–2.  doi:10.1136/jmg-2024-110183
 
Breast cancer after ovarian cancer in BRCA1 and BRCA2 pathogenic variant heterozygotes: lower rates for 5-years post chemotherapy
Evans DG, Morgan R,D, Crosbie EJ, Howell SJ, Forde C, Howell A, Lalloo F, Woodward ER
Genetics in Medicine   2024    doi: https:// doi.org/10.1016/j.gim.2024.101172
 
Atypia detected during breast screening and subsequent development of cancer: observational analysis of the Sloane atypia prospective cohort in England.
Freeman K, Jenkinson D, Clements K, Wallis MG, Pinder SE, Provenzano E, Stobart H, Stallard N, Kearins O, Sharma N, Shaaban A, Kirwan CC, Hilton B, Thompson AM, Taylor-Phillips S; Sloane Project Steering Group.
BMJ.   2024  Feb 1;384:e077039.   doi: 10.1136/bmj-2023-077039.
 
ESTRO Guidelines Consensus Recommendations on the integration of radiation therapy with targeted treatments for breast cancer
Meattini I, Becherini C, Caini S, Coles CE, Cortes J, Curigliano G, de Azambuja E, Isacke CM, Harbeck N, Kaidar-Person O, Marangoni E, Offersen BV, Rugo HS, Salvestrini V, Visani L, Morandi A, Lambertini M, Poortmans P, Livi L; Consensus Panellist Group. (Clarke RB)
Lancet Oncol.   2024  25(2):e73-e83 
 
State of the art modelling of the breast cancer metastatic microenvironment: Where are we?
Nuckhir M*, Withey D*, Cabral S*, Harrison H** and Clarke RB** (*Equal contributing first authors, **Co-corresponding Authors)
Journal of Mammary Gland Biology and Neoplasia   2024  29:14 
 
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial.
Oliveira M, Rugo HS, Howell SJ, Dalenc F, Cortes J, Gomez HL, Hu X, Toi M, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Nowecki Z, Park YH, Sohn JH, Tokunaga E, Yousef S, Zhukova L, Fulford M, Andrews H, Wadsworth I, D'Cruz C, Turner NC; CAPItello-291 study group.
Lancet Oncol  2024  Sep;25(9):1231-1244  doi: 10.1016/S1470-2045(24)00373-5. PMID: 39214106.
 
Tumor circadian clock strength influences metastatic potential and predicts patient prognosis in luminal A breast cancer
Shi-Yang Li, Jan A Hammarlund, Gang Wu, Jia-Wen Lian, Sacha J Howell, Robert B Clarke, Antony D Adamson, Cátia F Gonçalves, John B Hogenesch, Ron C Anafi, Qing-Jun Meng
Proceedings of the National Academy of Sciences of the United States of America (PNAS)  2024  February 6, 121,(7)  https://doi.org/10.1073/pnas.231185412
 
Capability and reliability of deep learning models to make density predictions on low-dose mammograms
Steven Squires, Alistair Mackenzie, Dafydd Gareth Evans, Sacha J. Howell, Susan M. Astley
J. Med. Imag  2024  11(4) 044506   https://doi.org/10.1117/1.JMI.11.4.044506
 
A novel preclinical model of the normal human breast
Wilby, A.J., Cabral, S., Zoghi, N., Howell, S.J., Farnie, G., Harrison, H.
J Mammary Gland Biol Neoplasia   2024  Volume 29, article number 9,   https://doi.org/10.1007/s10911-024-09562-4
 
Breast cancer research gaps: a questionnaire-based study to determine overall priorities and compare the priorities of patients, the public, clinicians and scientists.
Wilson RL, Boundouki G, Jackson RJ, Dave RV, Harvey JR, Wray J, Ballance L, Henderson JR, Duxbury P, Ibrahim I, Appanah V, Kirwan CC; North West Breast Research Collaborative.
BMJ Open  2024  Aug 28;14(8):e084573  doi: 10.1136/bmjopen-2024-084573.
 
Germline testing of BRCA1, BRCA2, PALB2 and CHEK2 c.1100delC in 1514 triple negative familial and isolated breast cancers from a single centre, with extended testing of ATM, RAD51C and RAD51D in over 400
Woodward ER, Lalloo F, Forde C, Pugh S, Burghel GJ,1 Schlecht H, Harkness EF, Howell A, Howell SJ, Gandhi A, Evans DG
J Med Genet doi: 10.1136/jmg-2023-109671  2024  21;61(4):385-391.  doi: 10.1136/jmg-2023-109671
 


Seminars